Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell RNA-seq analysis of PDX (Patient-Derived Xenograft) tumors isolated from mouse spleens, treated with Empty CAR, anti-CD72 H24 nanoCAR or anti-CD72 NbD4.13 nanoCAR.

ABSTRACT: Single-cell RNA-seq analysis was performed on human mantle cell lymphoma PDX (Patient-Derived Xenograft) tumors isolated from mouse spleens to examine gene expression changes after treatment of Empty CAR, humanized anti-CD72 nanobody-based CAR-T (“H24 nanoCAR”) or NbD4.13-based anti-CD72 nanoCAR-T.

ORGANISM(S): Mus musculus

PROVIDER: GSE290685 | GEO | 2026/02/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Framework humanization increases the affinity and potency of anti-CD72 nanobody-based CAR-T cells for B-cell malignancies

Project description:Anti-CD19 CAR T cells can induce remissions in some patients with B-cell malignancies. However, new immunotherapeutic targets are urgently needed for the many who relapse. We recently described CD72 as a promising target in B-cell leukemia and lymphoma, developing fully synthetic nanobody-based CAR-T cells (nanoCARs) against this antigen. Toward clinical translation, here we humanize our previous nanobody framework regions, derived from llama, and surprisingly discover a clone ("H24") with enhanced potency against B-cell tumors both in vitro and in vivo. In vitro, H24 nanoCARs showed improved cytokine secretion and favorable immunophenotypic properties. RNA sequencing before and after tumor exposure reveals humanized H24 CD72 nanoCARs have unique transcriptional programs compared to CD19 CAR T cells. We further find that H24 nanoCARs lead to sustained CD72 downregulation on tumors treated in vivo. Underpinning this improved potency, H24 had higher binding affinity to CD72 compared to a fully llama framework. Further affinity maturation moderately increased cytotoxicity versus antigen-low tumors. This work supports clinical translation of H24 CD72 nanoCARs, reveals potential mechanisms of resistance to this cellular therapy, and unexpectedly demonstrates that nanoCAR potency can be improved by framework alterations alone, without any change to the complementarity determining regions (CDRs) of the nanobody sequence.

2022-12-29 | GSE218791 | GEO

Single-cell RNA-seq analysis of PDX (Patient-Derived Xenograft) tumors isolated from mouse spleens, treated with Empty CAR, anti-CD72 H24 nanoCAR or anti-CD72 NbD4.13 nanoCAR.

Project description:Single-cell RNA-seq analysis of PDX (Patient-Derived Xenograft) tumors isolated from mouse spleens, treated with Empty CAR, anti-CD72 H24 nanoCAR or anti-CD72 NbD4.13 nanoCAR.

| PRJNA1229542 | ENA

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies II

Project description:Alternate strategies are needed for B-cell malignancy patients relapsing after CD19-targeted immunotherapy. Here, integrated cell surface proteomics and epigenetic analysis initially revealed CD72 as an optimal target for poor-prognosis MLL-rearranged B-ALL, which we further found to be expressed widely across B-cell malignancies. Using a recently-described, fully-in vitro system we selected CD72-specific nanobodies, incorporated them into CARs, and demonstrated robust activity against B-cell malignancy models, including CD19 loss. “Antigen escape profiling” modeled membrane proteome changes in the context of CD72 loss while pharmacologic SHIP1 inhibition increased CD72 surface density. We establish CD72-nanobody CAR T’s as a promising therapy for refractory B-cell malignancies.

2021-12-17 | GSE143179 | GEO

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I

2021-12-17 | GSE142447 | GEO

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies

2022-02-15 | PXD016800 | Pride

Framework humanization increases the affinity and potency of anti-CD72 nanobody-based CAR-T cells for B-cell malignancies

Project description:Framework humanization increases the affinity and potency of anti-CD72 nanobody-based CAR-T cells for B-cell malignancies

| PRJNA905454 | ENA

Deletion 9p drives B-cell leukemia by the concomitant loss of Pax5 and Cd72

Project description:We used microarrays to analyze gene expression changes in preleukemic cells from Cd72+/-;Pax5+/-, Pax5+/- and WT mice. The oncogenic role of 9p deletion in B-ALL has remained elusive since its discovery more than 40 years ago. We combined genomic analysis and functional models to show that the co-deletion of two contiguous genes, Pax5 and Cd72, confers gain in malignancy.

2026-02-09 | GSE302482 | GEO

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies

Project description:Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies

| PRJNA599148 | ENA

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I

Project description:Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies I

| PRJNA597032 | ENA

Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies II

Project description:Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in refractory B-cell malignancies II

| PRJNA599156 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data